Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Shirasugi Y et al. - No binding antibodies to romiplostim or thrombopoietin were detected. Romiplostim is safe and well tolerated in Japanese patients with chronic ITP and is effective in producing platelet count increases, consistent with the results from studies in non-Japanese patients. On the basis of these findings, a starting dose of 3ug/kg was recommended for phase III evaluation of romiplostim in Japanese patients with chronic ITP.

Related Articles

Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura
International Journal of Hematology, 10/12/09    Relevance Score: 70%

Immune thrombocytopenia associated with Mycoplasma pneumoniae infection: a case report and review of literature
Blood Coagulation & Fibrinolysis, 10/07/09    Relevance Score: 68%

Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia
International Journal of Hematology, 10/13/09    Relevance Score: 67%

Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura
Blood, 10/02/09    Relevance Score: 67%

Romiplostim in chronic immune thrombocytopenic purpura
Clinical Therapeutics, 10/23/09    Relevance Score: 66%

Today in Coagulation/Bleeding Dz...keeping you current

Intracranial Hemorrhage in Acute and Chronic Childhood Immune Thrombocytopenic Purpura over a Ten-Year Period: An Egyptian Multicenter Study
Acta Haematologica, 12/04/09

Hematological Issues in Critically Ill Patients with Cancer
Critical Care Clinics, 12/04/09

Pharmacokinetics and safety of fibrinogen concentrate
Journal of Thrombosis and Haemostasis, 12/03/09

Today in Pharmacology/Therapy...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address